Holen Sie sich die Stockscreener-App
3.39
0.59%
0.02
Schlusskurs vom Vortag:
$3.37
Offen:
$3.34
24-Stunden-Volumen:
13,511
Relative Volume:
0.31
Marktkapitalisierung:
$5.63M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-50.62M
KGV:
-0.0811
EPS:
-41.8255
Netto-Cashflow:
$-37.11M
1W Leistung:
-8.38%
1M Leistung:
-7.88%
6M Leistung:
-79.15%
1J Leistung:
-80.89%
1-Tages-Spanne:
$3.33
$3.46
1-Wochen-Bereich:
$3.2006
$3.855
52-Wochen-Spanne:
$3.12
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.39 | 5.59M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
479.29 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
671.87 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.39 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.34 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.22 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.350|Chg%:-0.110 - TradingKey
BCAB|Bioatla Inc|Price:3.550|Chg%:+0.180 - TradingKey
BCAB|Bioatla Inc|Price:3.481|Chg%:+0.091 - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioAtla Company Profile & Introduction - Moomoo
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Net Income Trends - DonanımHaber
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor Sentiment - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla Inc. (BCAB) Q4 2025 Earnings: EPS Beat Driven by Lower Operating Loss, Stock DeclinesConsensus Beat Rate - dars.gov.et
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineHigh Estimate Range - dars.gov.et
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BCAB Q4 2025 Earnings: EPS Surprise and Pipeline Focus Drive Positive SentimentEarnings Outlook Update - newsline.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentRevenue Surprise History - newsline.com
BCABBioAtla Inc Stock Price and Quote - Finviz
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):